GlobeNewswire by notified

Pixium Vision announces successful implantation of first patient in the Netherlands in Prima System European pivotal trial PRIMAvera

Share

Pixium Vision announces successful implantation of first patient in the Netherlands in Prima System European pivotal trial PRIMAvera

  • PRIMAvera clinical site opens at the Rotterdam Eye Hospital in the Netherlands
  • Follows successful implantations at clinical sites in France, Germany and the UK
  • New clinical sites to open in Spain and Italy
  • PRIMAvera read-out expected around the end of 2023

Paris, France, July26, 2022 – 07:00 CET – Pixium Vision SA (Euronext Growth Paris - FR0011950641; Mnemo: ALPIX), a bioelectronics company that develops innovative bionic vision systems to enable patients who have lost their sight to live more independent lives, announces today the successful implantation of the first patient in the Netherlands in the PRIMAvera pivotal trial in atrophic dry age-related macular degeneration (dry AMD).

This follows approval of the PRIMAvera study by the Dutch Ministry of Health, Welfare and Sport and the opening of the first PRIMAvera clinical site in the Netherlands at the Rotterdam Eye Hospital. The PRIMAvera study aims to confirm the safety and clinical benefits provided by the Prima System and is the last clinical step before seeking market approval in Europe. The study was initiated in Q4 2020 in France where the first patient was implanted in March 2021. Pixium Vision has since established additional clinical sites and implanted patients in Germany as well as the UK and anticipates recruitment will be completed by the end of 2022 leading to a read-out of the PRIMAvera study primary endpoints around the end of 2023.

"The PRIMAvera study has been making impressive progress with the implantation of patients in new clinical sites across Europe and we are very pleased to be joining these efforts to help bring the benefits of the innovative Prima Systemto those suffering from dry AMD," said Dr. Koen van Overdam, Consultant Ophthalmologist and Vitreoretinal Surgeon at the Rotterdam Eye Hospital. "The potential of the technology and the relative ease with which the small wireless implantcan be surgically placedunder the macula offer a real chance for patients who lost vision due to dry AMD and we look forward to contributing further to the PRIMAvera study."

The PRIMAvera study design is based on the positive data generated in the French feasibility study, showing the ability of patients with dry AMD to improve visual acuity with the Prima System.

A total of 38 patients will be enrolled in the PRIMAvera study, an open-label, baseline-controlled, non-randomized, multi-center, prospective, single-arm pivotal trial. The primary efficacy endpoint is the proportion of subjects with an improvement of visual acuity of logMAR 0.2 or more from baseline after 12 months, and the primary safety endpoint is the number and severity of device and procedure-related serious adverse events at 12 months follow-up. The study will include three years of follow-up, with an assessment of the primary endpoints at 12 months after implantation.

About Pixium Vision

Pixium Vision is creating a world of bionic vision for those who have lost their sight, enabling them to regain visual perception and greater autonomy. Pixium Vision’s bionic vision systems are associated with a surgical intervention and a rehabilitation period. Prima System sub-retinal miniature photovoltaic wireless implant is in clinical testing for patients who have lost their sight due to outer retinal degeneration, initially for atrophic dry age-related macular degeneration (dry AMD). Pixium Vision collaborates closely with academic and research partners, including some of the most prestigious vision research institutions in the world, such as Stanford University in California, Institut de la Vision in Paris, Moorfields Eye Hospital in London, Institute of Ocular Microsurgery (IMO) in Barcelona, University hospital in Bonn, and UPMC in Pittsburgh, PA. The company is EN ISO 13485 certified and qualifies as “Entreprise Innovante” by Bpifrance.

Forward-Looking Statements. This press release contains certain forward-looking statements. Although the Company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated. For a discussion of risks and uncertainties which could cause the Company's actual results, financial condition, performance or achievements to differ from those contained in the forward looking statements, please refer to the Risk Factors (“Facteurs de Risques”) section of the Company’s 2021 Half-Year Financial Report and other documents the Company files with the AMF, which is available on the AMF website (www.amf- france.org) or on the Company’s website.

For more information: To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.http://www.pixium-vision.com/fr

Follow us on To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.@PixiumVision; To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.www.facebook.com/pixiumvision

To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.www.linkedin.com/company/pixium-vision

To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

Contacts

Pixium Vision
Offer Nonhoff
Chief Financial Officer
investors@pixium-vision.com
+33 1 76 21 47 68
Media Relations

LifeSci Advisors
Sophie Baumont
sophie@lifesciadvisors.com
+33 6 27 74 74 49
Investor Relations
LifeSci Advisors
Guillaume van Renterghem
gvanrenterghem@lifesciadvisors.com
+41 76 735 01 31

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

A Step Forward in Human-Robot Collaboration: Han's Robot Opens A New Era of Intelligent Collaborative Robots13.8.2022 02:39:12 CEST | Press release

SHENZHEN, China, Aug. 12, 2022 (GLOBE NEWSWIRE) -- Wang Guangneng, general manager of Han's Robot, said that repetitive, mechanical, and dull work had left us no time to take care of our family and real life. Collaborative robots came into being to solve this issue, allowing robots and workers to work together to improve efficiency. However, this is only the first step. Han’s Robot is developing intelligent collaborative robots that do not require secondary development which users can buy and use according to their needs and costs. Han's Robot is invested and established by Han's Laser, the world's leading industrial laser processing and automation solution provider. It has attracted over 500 top global talents from 25 countries and regions. The core technology R&D team has accumulated more than ten years of industrial experience and mastered the core key technologies of intelligent robots. The product has the advantages of intelligent perception, zero-code programming, zero-sliding wh

Volta Finance Limited: Net Asset Value as at 31 July 202212.8.2022 18:15:00 CEST | Press release

Volta Finance Limited (VTA / VTAS) –July2022 monthly report NOT FOR RELEASE, DISTRIBUTION, OR PUBLICATION, IN WHOLE OR PART, IN OR INTO THE UNITED STATES ***** Guernsey, 12August2022 AXA IM has published the Volta Finance Limited (the “Company” or “Volta Finance” or “Volta”) monthly report for June. The full report is attached to this release and will be available on Volta’s website shortly (www.voltafinance.com). PERFORMANCE and PORTFOLIO ACTIVITY July saw a recovery from the losses faced the previous two months. The fund gained +4.5%, mainly driven by EUR CLO equity holdings (+2,7% contribution in NAV performance). Through asset classes, the monthly performances** were: -2.8% for Bank Balance Sheet transactions, +5% for CLO equity tranches; +2.3% for CLO debt; -5% for Cash Corporate Credit and ABS (together representing 2.3% of NAV). In the footsteps of most markets (July was one of the best months for the High Yield bonds market since years), the loan markets rallied and therefore C

CONDITIONS FOR RIKSBANK BID PROCEDURE KOMMUNINVEST BONDS12.8.2022 16:20:00 CEST | Press release

Bid procedure, 2022-08-16BondsKOMMUNINVEST I SVERIGE: 2410. SE0010469205. 2024-10-02 KOMMUNINVEST I SVERIGE: 2706, SE0016829048, 2027-06-15 BidsBids on interest and volume are entered via Bloomberg Bond Auction SystemBid date2022-08-16Bid times10.00-11.00Requested volume (corresponding nominal amount)2410: 200 mln SEK +/-100 mln SEK 2706: 200 mln SEK +/-100 mln SEK Highest permitted bid volume (corresponding nominal amount)2410: 200 mln SEK per bid 2706: 200 mln SEK per bid Lowest permitted bid volume (corresponding nominal amount)SEK 50 million per bidExpected allocation timeNot later than 11.15 (CET/CEST) on the Bid dateDelivery and payment date2022-08-18Delivery of bondsTo the Riksbank's account in Euroclear Sweden AB's securities settlement system 1 4948 6383General Terms and ConditionsGeneral Terms and Conditions General Terms and Conditions för the Riksbank’s Purchases of Bonds via Bid Procedure 2020:3. dated 20 November 2020 (see the Riksbank´s web). Stockholm, 2022-08-12 This i

CONDITIONS FOR RIKSBANK REVERSED AUCTIONS SEK GOVERNMENT BONDS12.8.2022 16:20:00 CEST | Press release

Bid procedure, 2022-08-19BondsSWEDISH GOVERNMENT: 1065. SE0017830730. 2033-11-11 Bid date2022-08-19Bid times09.00-10.00 (CET/CEST) on the Bid dateRequested volume (corresponding nominal amount)1065: 500 mln SEK +/-250 mln SEK Highest permitted bid volume (corresponding nominal amount)1065: 500 mln SEK per bid Lowest permitted bid volume (corresponding nominal amount)SEK 50 million per bidExpected allocation timeNot later than 10.15 (CET/CEST) on the Bid dateDelivery and payment date2022-08-23Delivery of bondsTo the Riksbank's account in Euroclear Sweden AB's securities settlement system 1 4948 6383 Stockholm, 2022-08-12 This is a translation of the special terms and conditions published on www.riksbank.se. In the case of any inconsistency between the English translation and the Swedish language version, the Swedish language version shall prevail. Complete terms and conditions can be retrieved at www.riksbank.se.

Mandalay Resources Corporation tillkännager resultatrapporten för andra kvartalet 202212.8.2022 15:44:02 CEST | Pressemelding

TORONTO, Aug. 12, 2022 (GLOBE NEWSWIRE) -- Mandalay Resources Corporation (”Mandalay” eller ”bolaget”) (TSX: MND, OTCQB: MNDJF) tillkännager resultatrapporten för kvartalet som slutade den 30 juni 2022. Bolagets sammanfattade och konsoliderade delårsrapporter för kvartalet som slutade den 30 juni 2022, tillsammans med ledningens diskussion och analys (”MD&A”) för motsvarande period, finns tillgängliga under bolagets profil på www.sedar.com och på bolagets webbplats på www.mandalayresources.com. Alla valutor i detta pressmeddelande avser USD om inget annat anges. Höjdpunkter under andra kvartalet 2022: Stärkt balansräkning – en förbättrad nettokassa med 47,9 miljoner USD i likvida medel och 41,5 miljoner USD i totala räntebärande utestående skulder;Konsoliderade kvartalsintäkter på 50,1 miljoner USD;Nettokassaflöde från den löpande verksamheten på 16,1 miljoner USD och fritt kassaflöde på 7,5 miljoner USD1;Konsoliderad kvartalsvis justerad EBITDA1 på 20,3 miljoner USD;Justerat nettoresu